版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
Epidermalgrowthfactorreceptor-tyrosinekinaseinhibitorinnon-small-celllungcancerYuh-MinChen,MD,PhD.ChestDept.,TaipeiVGH.6/9/20231YMCSurvival
(anti-apoptosis)PI3-KActivationoftheepidermalgrowthfactorreceptortyrosinekinase(EGFR-TK):apivotaldriverofcarcinogenesisEGFR-TKEGFRLigandRASRAFSOSGRB2PTENAKTSTAT3MEKGenetranscriptionCell-cycleprogressionDNAMycMycCyclinD1JunFosPPMAPKProliferation/
maturationChemotherapy/
radiotherapy
resistanceAngiogenesisMetastasisBalabanetal1996;Akimotoetal1999;Wells1999;Woodburn1999;
Hanahan2000;Raymondetal2000CyclinD1pYpYpY.6/9/20232YMCRppRExtracellularIntracellularMembranepKpKpppTGFaSubstrateSubstrateSignallingMoleculesProliferationInhibitApoptosisAngiogenesisMetastasisNucleusMonoclonalAntibodiesEGFRTyrosineKinaseInhibitors.6/9/20233YMCIDEAL1and2trialdesignGefitinib250mg/dayGefitinib
500mg/dayContinuegefitinibuntildisease
progressionorunacceptabletoxicityIDEAL,IressaTMDoseEvaluationinAdvancedLungcancer
RandomisationIDEAL1(n=209)
1or2priorregimensIDEAL2(n=216)
>2priorregimens
PrimaryendpointsObjectivetumourresponseSymptomimprovement(IDEAL2)Safety(IDEAL1).6/9/20234YMCMediantimetoimprovement-symptomsandQOL*Timeof1stassessmentMediantimetoimprovement,days
Symptom/QOLmeasureLCSFACT-L8*29*.6/9/20235YMCIDEAL1and2:overallsurvival
bysymptomimprovement(250mg/day)Probability1.00.80.60.40.20.0IDEAL1MonthsfromrandomisationImprovementNoimprovement2740183013.33.5Patients
(n)Deaths
(n)Median(months)024681012141618204458265613.63.7Patients(n)Deaths
(n)Median(months)1.00.80.60.40.20.0ProbabilityIDEAL2Monthsfromrandomisation02468101214161820Douillardetal2002;Lynchetal2003.6/9/20236YMCISEL(IRESSASurvivalEvaluationinLungCancer):
ClinicalTrialDesignRandomisationGefitinib(250mg)+*BSCPlacebo+*BSCSURVIVALSecondary:TTF,ORQoL,safetyPrimary
endpoint:ENDBENEFIT2:1ratio
AdoubleblindPhaseIIIsurvivalstudycomparingIRESSA(250mg)plusBSCvs.placeboplusBSCinpatientswithadvancedNSCLCwhohavereceived1–2priorchemotherapyregimensandarerefractoryorintoleranttotheirmostrecentregimen1692patientsin210centresacross28countries342patientsoforientaloriginNoJapanese/USsites*BSC=BestSupportiveCareLancet2005;366:1527-37.6/9/20237YMCISEL-OverallSurvivalPercentsurvivingTime(months)Atrisk:Gefitinib112910239017615884553252451751137645199
——
IRESSA
------PlaceboPlacebo563517446382289220160115774428201242GefitinibplaceboMedian(months)5.65.11yrsurvival27%21%HR=0.89(0.77,1.02),p=0.0871StratifiedlogranktestN=1692,deaths=976Coxanalysis,p=0.0299.6/9/20238YMCISELSurvival:OrientalsPercentsurvivingTime(months)Atrisk:Gefitinib235221199179145119957864514025128
——
IRESSA
------Placebo
Placebo107978474564335292213873115.5M9.5M.6/9/20239YMCJChemother2005;17:679.6/9/202310YMCRESULTS3CR,9PR,withaR.R.of33.3%
SD14,controlrateof72.2%Alltreatment-relatedtoxicitieswerefewandmildinseverity,exceptonepatientsufferedfromreversiblegrade3interstitialpneumonitis
JChemother2005;17:679.6/9/202311YMC%SurvivalMediansurvival:9.5monthsOne-yearsurvivalrate:45.1%JChemother2005;17:679.6/9/202312YMC%SurvivalFig.10102030405060708090100036912151821MonthsCompleteorpartialresponse(n=12)median20.1MStableorprogressivedisease(n=24)median4.7MSurvivalaccordingtoresponseornot15.4月JChemother2005;17:679.6/9/202313YMCStudyDesignofBR.21
Stratifiedby:CentrePS(0/1vs2/3)Responsetoprior
treatment(CR/PR:SD:PD)
Priorregimens(1vs2)Priorplatinum
(yesvsno)Tarceva
150mgdailyPlaceboRANDOMISEPS=performancestatus21NEnglJMed2005;353:123–32.6/9/202314YMCBR.21:Significant
clinicalpredictorsofresponsetoTarcevaTarceva
treatedpts(n)R.R.(%)
pvalue*GenderFemale(146)14.40.006Male(281)6.1HistologyAdenocarcinoma(209)13.9<0.001Other(218)4.1EthnicityAsian(53)18.90.02Other(374)7.5Eversmoked**Yes(311)3.8<0.001No(93)24.7Unknown(23)13.0*Significancebetweensubgroups**DatacollectedretrospectivelyInmultiplelogistic-regressionanalyses,onlyneverhavingsmoked(p<0.001)andadenocarcinomahistology(p=0.01)wereassociatedwithresponseShepherdetal.NEJM2005;353:123.6/9/202315YMCImprovementinSurvivalwithTarceva42.5%improvementinmediansurvivalSurvivaldistributionfunctionSurvivaltime(months)HR=0.73,p<0.001*1.000.750.500.2500 5 10 15 20 25 30TarcevaPlaceboNEnglJMed2005;353:123–32
Tarceva
(n=488)
Placebo
(n=243)
Mediansurvival(months)
6.7
4.7
1-yearsurvival(%)
31
21
.6/9/202316YMCBR.21:Timetosymptomdeterioration(months)
Placebo
Tarceva179
179
153
n348
353
298
n1.9
(1.8–2.8)2.9
(2–4.8)3.7
(2–4.9)Median
(95%CI)0.02
2.8
(2.4–3)Pain
0.01
4.7
(3.8–6.2)Dyspnea
0.04
4.9
(3.8–7.4)Cough
pvalue*Median
(95%CI)*Log-ranktest,unadjustedformultiplesymptomsBezjakA,etal.JClinOncol2006;24:3831–7ShepherdF,etal.NEnglJMed2005;353:123–32.6/9/202317YMCTRUST:TarcevaMO18109
AnexpandedaccessclinicalprogramofTarceva(erlotinib)inptswithadvancedstageIIIB/IVNSCLC
LungCancer2008.6/9/202318YMCPatientPopulation&ResponseFromMay2005toJuly2006,300patientswereenteredfrom14hospitalsinTaiwan.Thisanalysiswasbasedon299patientswhoreceivedatleastonedoseofTarceva..6/9/202319YMCResponserateandcontrolratebypretreatmentcharacteristicsandskintoxicityPatientcharacteristicsPatientnumberResponserate(%)p-valueControlrate(%)p-valueGenderMaleFemale1401332037.60.001363.682.70.0004Age<65
6516011334.420.40.011573.172.60.9185Performancestatus0/123226351228.822.941.70.46910.339272.671.483.30.88850.4124StageIIIBIV5621517.931.20.049269.673.50.5651HistologyAdenocarcinomaSquamouscellcarcinoma1904834.712.50.00277960.40.0079PresenttreatmentasSecondlineThirdline16710229.926.50.541370.776.50.2983SmokingstatusNon-smokerFormerorcurrentsmoker15811533.521.70.03379.164.40.0067Skintoxicity-1NorashRash2924410.330.70.021641.476.6<0.0001Skintoxicity-2Norashorgrade1Rashgrade2,3,or411915419.335.70.00361.381.80.0002Thebestresponserateswerea29%partialresponseand44%stablediseasein273patientswhohadresponsedataavailable.Non-smoking(p=0.033),adenocarcinoma/BAC(p=0.0027),female(p=0.0013),agedlessthan65years(p=0.0115),stageIV(p=0.0492),patientswithskinrash(p=0.0216),andahighergradeofskinrash(p=0.003)weresignificantlycorrelatedwithresponsetotreatment..6/9/202320YMC0.000.250.500.751.00Progressionfreesurvival(Months)061020CensoredobservationsFig.1Freefromprogression8421214161822Timetodiseaseprogressionof299NSCLCptstreatedwitherlotinib.Themediantimetodiseaseprogressionwas5.6months(95%C.I.:4.4–6.5months,45ptscensored).6/9/202321YMCEGFR-TKIvs.chemotherapeuticagentsinsalvagechemotherapy.6/9/202322YMCInconclusion,bothchemotherapeuticagents,suchasdocetaxelaloneorgemcitabine+vinorelbine,andgefitinib,areappropriatesalvageregimensforChineseNSCLCptswhohavefailedpreviouschemotherapy.However,gefitinibhasabettersafetyprofileandprobablybettersurvivalthanthechemotherapeuticagents,andwouldbeanappropriatealternativechoiceforsalvagechemotherapy,eveninasecond-linesettingforChinesepts.
JThoracOncol2006;1:545-50.6/9/202323YMCEfficacyofSalvageTherapyinNSCLCTrialScheduleR.R.,%MTP,MMSur,M1-Yr,%SingleagentGemcitabine1200mg/m2D1,8,15q4wks12.52.17.540Docetaxel3535mg/m2D1,8,15q4wks17.24.28.433.44040mg/m2D1,8q3wks10.93.57.4357575mg/m2D1q3wks6.12.87.830.3Gefitinib250mgdaily33.34.79.340.8DoubletDocetaxel+IfosfamideD60mg/m2+I3gm/m2D1q3wks1058.226.1Docetaxel+GemcitabineD30mg/m2+G800mg/m2D1,8q3wks36.13.85.733.3Vinorelbine+GemcitabineV20mg/m2+G800mg/m2D1,8,15q4wks31.34.68.334.3Vinorelbine+CisplatinV20mg/m2D1,8,15+C50mg/m2D1q4wks9.53.77.619.7.6/9/202324YMCSalvageChemotherapy(n=342)Grade?Neutroopenia.6/9/202325YMCSalvageChemotherapy(n=342)Grade?FatigueDocetaxel40andvinorelbinepluscisplatininducedmorefrequentseverefatiguethanotherregimens.Patientsthatreceivedsingle-agentgemcitabineandgefitinibreportednoseverefatiguesensation..6/9/202326YMCInterestINTEREST(gefitinibvs.docetaxelinptswithLAormeta.NSCLCpre-treatedwithplatinum-basedchemotherapyWCLC20071466ptsfromMar2004toFeb2006.6/9/202327YMCInterestQoFandsymptomimprovementWCLC2007.6/9/202328YMCInterestWCLC2007.6/9/202329YMCInterestOverallsurvival.6/9/202330YMCClinicalcharacteristics&responserate(ptnumber=1974)IntJClinOncol2006;11:190–8.6/9/202331YMCEGFRMutationEurJCancer2006:17-23NEnglJMed2004;350:2129-39.6/9/202332YMCFailureofDoubletChemotherapyplusEGFR-TKIINTACTI,IITRIBUTE,TALENT.6/9/202333YMCGiaccone.JCO2004;22:777OverallSurvivalofINTACT-1inEachTreatmentGroup(GEM+CDDPc/sIressa)PoorsurvivalforthoseuseIressawithGEM+CDDP.6/9/202334YMCCanwefurtherprolongdisease-freesurvivalandoverallsurvival?FailureofdoubletchemotherapyplusTKIINTACTI,II(Gefitinib);TRIBUTE,TALENT(Erlotinib)MajorityperformedinCaucasianptsUnknownforAsianptswithhighEGFRmutationrateToassesstheefficacyofaddingchronicintermittentlow-dosevinorelbinetogefitinibtreatmentforadenocarcinomaoflungwhofailedtwoormoreregimensofchemotherapy.
.6/9/202335YMC.6/9/202336YMCConclusionsAdditionoflow-dosevinorelbinetogefitinibhasshownhighefficacyinadenocarcinomalungcancerpatientswhohavefailedtwopreviousregimensofchemotherapy.GiventhefactthattherearefournegativephaseIIIrandomizedtrialsofEGFRTKI'swithchemotherapy(INTACTIandII,TRIBUTE,TALENT),
onlystudiesinselectedEGFRmutation-enrichedpatientpopulationscanbejustifiedatthistimeforfurtherclinicaltrialscombiningchemotherapywithEGFRTKIs..6/9/202337YMC%FreefromProgression1-yearprogression-freesurvivalratewas57.1%intheGVarmand21.2%intheGarm(p=0.008).6/9/202338YMCErlotinibinducesG1arrestwhichcanblockM-phaseactivityofdocetaxelDocetaxelinducesM-phasearrestandapoptosisthatisenhancedbyerlotinibSequence–specificInteractionClinLungCancer2006;7:385.6/9/202339YMCFirst-lineAsianSequentialTarcevaplusChemotherapyTrial(FAST-ACT):StudyDesignPlaceboErlotinib150mg/dayPreviouslyuntreatedstageIIIB/IVNSCLC(n=150)R11PDSixcyclesgemcitabine+cisplatinorcarboplatin+placebo;q4wksSixcyclesgemcitabine(d1,8)+cisplatin(d1)orcarboplatin(d1)+erlotinib(d15–28);q4wksPDStratifiedbycentre,stage,
histology,smokingstatusStudytreatmentPost-treatmentScreeningPost-studyGemcitabine1250mg/m2(d1,8);cisplatin75mg/m2ORcarboplatin5×AUC(d1);erlotinib150mg/day(d15–28)PASCO2008;26:a8031.6/9/202340YMCTimetoDiseaseProgression1.00.80.60.40.20
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36Time(weeks)
38 40 42 44 46 48 50 52 54 56 58
76 72 72 72 64 61 58 58 58 52 50 50 46 37 36 32 26 15 14 78 76 76 76 67 59 58 56 50 43 43 41 35 25 24 22 16 8 7
12 10 9 8 7 5 5 5 3 1 0 5 4 2 1 1 1 1 1 1 1 0No.atriskErlotinibPlaceboEarlyandconsistentseparationofcurvesMedianTTP
(weeks)GC-erlotinib31.4GC-placebo24.1Log-ranktestp=0.0185HR=0.5695%CI:0.37–0.8424.131.4PASCO2008;26:a8031R.R.36.8%24.4%Howlongshouldchemotherapybegiven(noPDSatmaintenancephase)GEMCDDPdose(controlarm)islessthanusualBetterforthoseCaucasianswhohavehigher%ofEGFRwildtype.6/9/202341YMCFirstlinetreatmentwithEGFR-TKIsinthosewithEGFRmutatedpatients.6/9/202342YMC98ptsunderwentEGFRscreeningandmutationsweredetectedin34(35%).EGFRmutations:exon19deletions(53%),L858R(26%)31ptsreceivedgefitinib,R.R.55%,medianprogression-freesurvival9.2M.Therapywaswelltolerated.JClinOncol2008;26:2442-9.6/9/202343YMCPercentchangeinmeasurabletumoratbestresponse,byindividualpatientJClinOncol2008;26:2442-9.6/9/202344YMCKaplan-Meiercurvesfor(A)progression-freesurvivaland(B)overallsurvivalamongalltreatedptsJClinOncol2008;26:2442-9PFS9.2MSur17.5M.6/9/202345YMCGefitinibfirstlinetreatmentinenrichedEGFR-mutatedNSCLCinNTUHN=106(adenoca97,non-adeno9)PtNoRR,%DCR,%MedianTTF,MMedianOS,MAll10650.982.15.522.4EGFRmutated556987.3824wildtype352068.63.412.9notdone1656.393.85.6NRJCO2008;26:2745-53PtNoRR,%MedianTTF,MExon19deletion20958.9Exon21L858R2373.99.1.6/9/202346YMCPredictiveFactorsofResponsetoGefitinibin152EGFRmutatedpatientsinNTUHVariablesNoResponserates(%)UnivariatePMultivariatePN=152L858R7565.30.646
DelinExon197768.8
Chemonaive9175.80.0050.006Chemo-treated6154.1
Female11071.80.0450.053Male4254.8
Smoker2254.60.175
Non-smoker13069.2
<=65years7017.90.789>65years8213.7
WuJYetal.AJRCCM2008.6/9/202347YMCNosurvivaldifferencein152chemonaiveorchemo-treatedEGFRmutatedpatientsinNTUHChmona?vegefitinib(n=91)Chemotherapytreatedgefitinib(n=61)logrankChmona?vegefitinib(n=91)Chemotherapytreatedgefitinib(n=61)logrank=0.24WuJYetal.AJRCCM2008.6/9/202348YMC2003.9.15s/p4lineC/Tsince20010629,PS3FiO250%2003.9.29Iressa2weeksPS1roomairAnother1.5year.6/9/202349YMCMs.ReeHxNo3167688775Y/O20021202SOBformonths,PS2-3,NC3L/minpreC/T20050804postNGC;taxotere;underIressa-N,PS0.6/9/202350YMCs/prenaltransplantationwith
adenocarcinoma,LUL,&brain,meningealcarcinomatosisNotappropriateforchemotherapy,receivefirstlineTarcevawithtotaldisappearanceofmeningealcarcinomatosis&brainmetastases(brainMRIfollow-up6monthsafterTarcevatreatment)TarcevafirstlinetreatmentPatientstillaliveatpresent.6/9/202351YMCT790MPaoetal.PLoSMed2005;2:1-11Kwaketal.ProNatAcadSciUSA2005;102:7665-708of16TKItreatedhad2ndmutation:7of8wasT790M
ClinCancerRes2006;12:6494-501T790Maccountsfor50%acquiredresistancetoEGFR-TKIsC-METamplificationacco
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 鄉(xiāng)村公路擴(kuò)建項目水泥路施工合同
- 村莊水廠水源地開發(fā)與保護(hù)合同
- 建筑業(yè)供應(yīng)鏈與協(xié)同創(chuàng)新模式
- 火車站消防設(shè)施改造合同樣本
- 2025銷售汽車購銷合同
- 分布式光伏電池板與儲能技術(shù)選擇
- 2023外貿(mào)合同范文(23篇)
- 2023年注冊安全工程師職業(yè)資格考試《安全生產(chǎn)專業(yè)實務(wù)煤礦安全》模擬真題
- 2023年中級注冊安全工程師之安全實務(wù)化工安全考試題庫
- 泉州華光職業(yè)學(xué)院《特殊教育學(xué)校語文課程與教學(xué)》2023-2024學(xué)年第一學(xué)期期末試卷
- DBJ∕T15-231-2021 城市軌道交通既有結(jié)構(gòu)保護(hù)監(jiān)測技術(shù)標(biāo)準(zhǔn)
- 設(shè)備供貨安裝方案(通用版)
- 政府預(yù)算理論與實務(wù)(第四版)全套教學(xué)課件
- 新教材人教版高中地理必修一 4.2.1海水的性質(zhì)和運動(第一課時 海水的性質(zhì)) 教學(xué)課件
- S11型油浸式電力變壓器使用說明
- (完整)小學(xué)初中課程體系圖
- XX樓基坑錨索拉拔試驗報告教學(xué)文案
- 《我與地壇》PPT課件(PPT 48頁)
- 花生生長全過程圖譜PPT課件(PPT 15頁)
- 組織的高效溝通ppt課件
- 中考、高考標(biāo)準(zhǔn)答題卡答題注意事項ppt課件
評論
0/150
提交評論